Huons Group said it unveiled its latest aesthetic products and technologies at the Dubai World Dermatology and Laser Conference & Exhibition (Dubai Derma 2025) held from April 14 to 16 at the Dubai World Trade Center in Dubai, the UAE.

Humedix, Huons Meditech, and Huons BioPharma showcased their flagship products at the 24th edition of Dubai Derma, the largest dermatology-focused event in the Middle East and North Africa (MENA) region.

Humedix signed a supply agreement for its hyaluronic acid filler, Elravie, for Saudi Arabia, Lebanon, and Syria. Elravie, approved in Korea, the EU, China, and Russia, is exported to 19 countries.

Huons Meditech presented Dermashine Pro, an automatic mesotherapy injector designed to deliver high-molecular-weight hyaluronic acid across the face. The Dermashine series has reached cumulative sales of 20,000 units as of the end of 2024.

Huons BioPharma showcased its botulinum toxin products, which are approved in 15 countries, including Russia, Thailand, and Iraq, and are awaiting approval in China.

Huons Group emphasized plans to strengthen its foothold in the Middle Eastern market by leveraging Dubai Derma to build strategic partnerships and expand global reach.